Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio

  • Sustained R&D productivity has generated 14 clinical development candidates against 11 discrete molecular targets
  • Diverse immuno-oncology and targeted cancer therapy portfolios comprised of both large and small molecule therapies
  • Live webcast presentation from AACR taking place Sunday, April 17, 2016 at 7:00 p.m. CDT / 8:00 p.m. EDT

WILMINGTON, Del.--()--Incyte Corporation (Nasdaq: INCY) will highlight the productivity of its drug discovery and development organization and aspects of its development portfolio at an investor event on Sunday, April 17, 2016 at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana.

The event will include a discussion of Incyte’s second-generation PI3Kδ inhibitor, INCB50465; the Company’s immuno-oncology portfolio, including its anti-GITR antibody, INCAGN1876, anti-OX40 antibody, INCAGN1949, and emerging data with its small molecule BRD inhibitor, INCB54329; as well as its targeted epigenetic therapies, including a novel LSD1 inhibitor entering Phase 1 development, INCB59872.

“Incyte operates with the conviction that investment in basic research can translate into innovative therapies that can address important unmet medical needs. To that end, we are pleased to be able to highlight such a broad collection of abstracts from our emerging development portfolio at this year’s AACR Annual Meeting,” stated Reid Huber, Ph.D., Incyte’s Chief Scientific Officer. “The research team’s productivity is a result of the quality of our scientific organization and the efficiency of our R&D model.”

As part of its succession plan, Incyte also announced that after almost 13 years at the Company, Dr. Richard Levy, Chief Drug Development Officer, is retiring effective April 30, 2016. Dr. Steven Stein, Incyte’s Chief Medical Officer, will now assume all of Dr. Levy’s responsibilities. Dr. Levy was instrumental in building the broad and diverse portfolio Incyte has today, and developing Jakafi® (ruxolitinib), the Company’s proprietary JAK 1/JAK 2 inhibitor.

Webcast Information

The investor event will be webcast live on Sunday, April 17, 2016 at 7:00 p.m. CDT / 8:00 p.m. EDT and can be accessed via the Investor’s section of www.incyte.com under “Events and Presentations.” Investors interested in listening to the live webcast should log-on before the start time to download any required software. The presentation slides will also be made available following the event.

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.

Follow @Incyte on Twitter at https://twitter.com/Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s development pipeline and the potential of the Company’s product candidates, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2015. Incyte disclaims any intent or obligation to update these forward-looking statements.

Contacts

Incyte Corporation
Media
Catalina Loveman, +1 302 498 6171
cloveman@incyte.com
or
Investors
Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com

Release Summary

Incyte Investor Event at AACR 2016 to Highlight Innovative and Diversified Research and Development Portfolio

Contacts

Incyte Corporation
Media
Catalina Loveman, +1 302 498 6171
cloveman@incyte.com
or
Investors
Michael Booth, DPhil, +1 302 498 5914
mbooth@incyte.com